Researchers at Stanford University have developed a software that applies correction algorithms on sequence data from cell-free DNA (cfDNA) in blood samples to estimate total T and B cell counts.
Researchers at Stanford have developed a novel T cell engineering platform that leverages constitutively active interleukin-9 receptor (IL-9R) signaling to improve the efficacy and scalability of immunotherapies for solid tumors.
Stanford scientists have developed fully human CD19-targeted CAR T cells designed to overcome the limitations of current CAR T cell therapies, particularly in treating low CD19 density blood cancers.
Stanford researchers have developed a novel, multi-specific chimeric antigen receptor (CAR) T-cell therapy designed to overcome the key challenges of treating solid tumors, including tumor heterogeneity, immune evasion, and CAR T-cell exhaustion.
Stanford researchers in Prof. Michelle Monje's lab have developed a method for treating cognitive impairment (aka brain fog) caused by cancer immunotherapy.
Stanford researchers have developed a highly effective B7-H3 chimeric antigen receptor (CAR) for CAR-T cell therapy, designed to enhance binding and cytotoxicity against B7-H3 expressing solid tumors, offering a promising treatment for various cancers.
Stanford scientists have developed a trivalent CAR T cell that targets three proteins that are essential for self-renewal and differentiation of leukemic stem cells.
Scientists in Dr. Howard Chang's lab have developed ESCAPE-seq (Enhanced Single Chain Antigen Presentation sequencing) to identify novel neoantigen sequences for the development of immunotherapies.
Stanford researchers have developed a non-viral, homology-independent method for precise targeted DNA insertions into T-cells using electroporation and CRISPR/Cas9, enabling cost-effective production of CAR T-cells for T-cell therapies.
Researchers in Prof. Crystal Mackall's laboratory at Stanford University are focused on translational research related to cancer immunotherapy, including basic T-cell function and tumor immunology.
Stanford researchers have patented a system for precise genetic modification of human embryonic stem cells (ECSs) and induced pluripotent stem cells (iPSCs).
Stanford researchers have developed a novel approach to selectively regulate and monitor immune responses in specific mucosal tissues, using the GPCR receptor GPR25 and its ligand CXCL17, which targets lymphocyte localization to non-intestinal mucosal tissues, enabling selecti
Stanford inventors have developed a method to efficiently differentiate human pluripotent stem cells (hPSCs) into nearly pure populations of human blood progenitors or blood vessel cells in a Petri dish.